Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM)
详细信息 查看全文
- 作者：Andra V Krauze (1)
Minhee Won (2)
Christian Graves (1)
Ben W Corn (3)
Thierry M Muanza (4)
Steven P Howard (5)
Arul Mahadevan (6)
Christopher J Schultz (7)
Michael L Haas (8)
Minesh P Mehta (9)
Kevin A Camphausen (1) (10) - 关键词：VEGF (vascular endothelial factor) ; Glioblastoma Multiforme (GBM) ; Urinary biomarker ; Radiation therapy ; Tumor recurrence
- 刊名：Biomarker Research
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：1
- 期：1
- 全文大小：195 KB
- 参考文献：1. Ohgaki H, Kleihues P: Genetic alterations and signaling pathways in the evolution of gliomas. / Cancer Sci 2009, 100:2235-241. w window">CrossRef
2. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK: / WHO classification of tumors of the CNS. 4th edition. Lyon, France: IARC Press; 2007.
3. National Comprehensive Cancer Network: / Anaplastic gliomas/Glioblastoma. Accessed 10/1/2013. [www.nccn.org/professionals/physician_gls/pdf/cns.pdf" class="a-plus-plus">http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf] Accessed 10/1/2013.
4. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D: Angiogenesis in glioma: biology and molecular pathophysiology. / Brain Pathol 2005, 15:297-10. w window">CrossRef
5. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, / et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. / N Engl J Med 2005, 352:997-003. w window">CrossRef
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, / et al.: Effect of radiotherapy with concomittant and adjuvant Temozolomide versus radiotherapy alone on survival in glioblastoma in randomized phase III study: 5-year analysis of the EORTC-NCIC Trial. / Lancet Oncol 2009, 10:459-66. w window">CrossRef
7. Vihinen P, K?h?ri VM: Matrix metalloproteinases in cancer: Prognostic markers and therapeutic agents. / Int J Cancer 2002, 99:157-66. w window">CrossRef
8. Burke PA, DeNardo SJ: Antiangiogenic agents and their promising potential in combined therapy. / Crit Rev Oncol Hematol 2001, 39:155-71. w window">CrossRef
9. Robles Irizarry L, Hambardzumyan D, Nakano I, Gladson CL, Ahluwalia MS: Therapeutic targeting of VEGF in the treatment of glioblastoma. / Expert Opin Ther Targets 2012,16(10):973-84. w window">CrossRef
10. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, / et al.: Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. / JCO 2004,3(22):499-06.
11. Zhou ZH, Cui XN, Xing HG, Yan RH, Yao DK, Wang LX: Changes and prognostic value of serum vascular endothelial growth factor in patients with differentiated thyroid cancer. / Med Princ Pract 2012. Epub ahead of print
12. Riihij?rvi S, Nurmi H, Holte H, Bj?rkholm M, Fluge O, Pedersen LM, / et al.: High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapya. / Eur J Haematol 2012. Epub ahead of print
13. Hormbrey E, Gillespie P, Turner K, Han C, Roberts A, McGrouther D, / et al.: A critical review of vascular endothelial growth factor analysis in peripheral blood: is the current literature meaningful? / Clin Exp Metastasis 2002, 19:651-63. w window">CrossRef
14. Jelkmann W: Pitfalls in the measurement of circulating vascular endothelial growth factor. / Clin Chem 2001,47(4):617-23.
15. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE: Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. / Clin Sci (Lond) 1998,94(4):395-04.
16. Kirk MJ, Hayward RM, Sproull M, Scott T, Smith S, Cooley-Zgela T, / et al.: Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens. / J Cell Mol Med 2008,12(4):1250-255. w window">CrossRef
17. Hayward RM, Kirk MJ, Sproull M, Scott T, Smith S, Cooley-Zgela T, / et al.: Post-collection, pre-measurement variables affecting VEGF levels in urine biospecimens. / J Cell Mol Med 2008,12(1):343-50. w window">CrossRef
18. Dvorak HF: Angiogenesis: update 2005. / J Thromb Haemost 2005, 3:1835-842. w window">CrossRef
19. Zhang X, Groopman JE, Wang JF: Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1. / J Cell Physiol 2005, 202:205-14. w window">CrossRef
20. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, / et al.: Expression of the vascular permeability factor/vascular endothelial growth factorgene in central nervous system neoplasms. / J Clin Invest 1993, 91:153-59. w window">CrossRef
21. Gilbert MR, Wang KD, Aldape R, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal A, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Mehta M: RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide(TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma [abstract]. / J Clin Oncol 2011,29(29):S18.
22. Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, Mehta M, Curran W, Phan SC: Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. / Int J Radiat Oncol Biol Phys 2007,69(3):831-38. Epub w window">CrossRef
23. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, / et al.: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. / J Natl Cancer Inst 1993,85(9):704-10. w window">CrossRef
24. Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran WJ Jr, Mehta MP: Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. / Int J Radiat Oncol Biol Phys 2011,81(3):623-30. w window">CrossRef
25. Jain RK: Molecular regulation of vessel maturation. / Nat Med 2003,9(6):685-93. w window">CrossRef
26. Osada H, Tokunaga T, Nishi M, Hatanaka H, Abe Y, Tsugu A, / et al.: Overexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma. / Anti Cancer Res 2004, 24:547-52.
27. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, / et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. / J Clin Oncol 2009,27(28):4733-740. w window">CrossRef
28. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, / et al.: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. / J Clin Oncol 2009,27(5):740-45. w window">CrossRef
29. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, / et al.: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. / J Clin Oncol 2011,29(2):142-48. w window">CrossRef
30. Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M: Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. / J Neurooncol 2007, 83:91-3. w window">CrossRef
31. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, / et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. / N Engl J Med 2000, 343:1350-354. w window">CrossRef
32. Aldape K, Wang M, Sulman E, Hegi M, Colman H, Jones G, / et al.: RTOG 0525: molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. / J Clin Oncol 2011, 29:S18. [Abstract] w window">CrossRef
33. Reifenberger G, Hentschel B, Felsberg J, / et al.: Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. / Int J Cancer 2012, 131:1342-350. w window">CrossRef
34. Gallego Perez-Larraya J, Ducray F, Chinot O, / et al.: Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. / J Clin Oncol 2011, 29:3050-055. w window">CrossRef
35. Wick W, Platten M, Meisner C, NOA-08 Study Group of the Neuro-oncology Working Group (NOA) of the German Cancer Society, / et al.: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. / Lancet Oncol 2012, 13:707-15. w window">CrossRef
36. Malmstrom A, Gr?nberg BH, Marosi C, / et al.: Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy for patients aged over 60 years with glioblastoma: the Nordic randomized phase 3 trial. / Lancet Oncol 2012. in press
37. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, / et al.: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. / Cancer Cell 2006,9(3):157-73. w window">CrossRef
38. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, / et al.: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. / Cancer Cell 2010,17(1):98-10. w window">CrossRef - 作者单位：Andra V Krauze (1)
Minhee Won (2)
Christian Graves (1)
Ben W Corn (3)
Thierry M Muanza (4)
Steven P Howard (5)
Arul Mahadevan (6)
Christopher J Schultz (7)
Michael L Haas (8)
Minesh P Mehta (9)
Kevin A Camphausen (1) (10)
1. National Cancer Institute/NIH, Bethesda, MD, USA
2. RTOG Statistical Center, Philadelphia, PA, USA
3. Tel-Aviv Medical Center, Tel-Aviv, Israel
4. McGill University, Montreal, QC, Canada
5. University of Wisconsin Hospital, Madison, WI, USA
6. Dartmouth Hitchcock Medical Centre, Lebanon, NH, USA
7. Medical College of Wisconsin, Milwaukee, WI, USA
8. Reading Health System, West Reading, PA, USA
9. Northwestern Memorial Hospital, Chicago, IL, USA
10. Radiation Oncology Branch, National Cancer Institute, NIH, 10 Center Drive, MSC 1682, Building 10, CRC, Rm B2-3500, Bethesda, MD, 20892, USA - ISSN：2050-7771
文摘
Background Glioblastoma Multiforme (GBM) is the most common primary malignant tumor of the central nervous system. Standard of care includes maximal resection followed by chemoradiotherapy. Tumors need adequate perfusion and neovascularization to maintain oxygenation and for removal of wastes. Vascular endothelial growth factor (VEGF) is a well characterized pro-angiogenic factor. We hypothesized that the increases in urinary VEGF levels would occur early in the course of tumor recurrence or progression. We examine the feasibility of collecting and analyzing urinary VEGF levels in a prospective, multi-institutional trial (Radiation Therapy Oncology Group, RTOG, 0611) as well as the role of VEGF as a marker of tumor recurrence. Method We evaluated VEGF levels in urine specimens collected post-operatively, at the conclusion of radiation therapy (RT) and one month following RT. Urinary VEGF levels were correlated with tumor progression at one year. VEGF levels were measured by enzyme-linked immunosorbant assay in urine specimens and normalized to urinary creatinine levels. Sample size was determined based on a 50% 1-year recurrence rate. With a sensitivity and specificity of 80%, the expected 95% confidence interval was (0.69, 0.91) with 100 patients. A failure was defined as documented disease progression, recurrence or death before one year. Results 202 patients were enrolled between February-2006 and October-2007. Four patients were ineligible as they did not receive RT. Of the remaining 198 patients, 128 had all three samples collected. In this group, 35 patients (27.3%) did not progress, 89 (69.5%) had progression and 4 (3.1%) died without evidence of progression. Median VEGF levels at baseline were 52.9?pg/mg Cr (range 0.2- 15,034.4); on the last day of RT, 56.6 (range 0-,377.1); and at one month follow-up, 70.0 (range 0.1-1813.2). In patients without progression at 1-year, both baseline VEGF level and end of RT VEGF level were lower than those of patients who progressed: 40.3 (range 0.2-350.8) vs. 59.7 (range 1.3-15,034.4) and 41.8 (range 0-56.8) vs. 69.7 (range 0-,377.1), respectively. This did not reach statistical significance. Comparison of the change in VEGF levels between the end of RT and one month following RT, demonstrated no significant difference in the proportions of progressors or non-progressors at 1-year for either the VEGF increased or VEGF decreased groups. Conclusion Urine can be collected and analyzed in a prospective, multi-institutional trial. In this study of patients with GBM a change in urinary VEGF levels between the last day of RT and the one month following RT did not predict for tumor progression by one year.